Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab in VRD Induction/Consolidation and Lenalidomide Maintenance for Newly Diagnosed Myeloma
NCT02495922Phase 3Completed
- Start
- Jun 2015
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of elotuzumab in multiple myeloma (MM). Started Jun 2015; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02495922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495922.